Monday, September 20th was the first day of the WMS 2021 Virtual Congress, and a day devoted to symposia sponsored by various companies developing therapeutic treatments for neuromuscular disorders. Most […]
It’s that time of year again, when neuromuscular disease researchers clear their calendars for the Annual International Congress of the World Muscle Society (WMS), the largest conference focused solely on […]
CureDuchenne Cares Advocacy Efforts Succeed in Adding Duchenne to the Social Security Administration Compassionate Allowance List (CAL) Social Security Disability Insurance (SSDI) benefits are a financial lifeline for millions of […]
CureDuchenne Ventures’ early funding of Edgewise in September of 2019 is returning more good news. In November of 2020, Edgewise began its Phase 1 clinical trial on EDG-5506, an experimental […]
CureDuchenne Link™ is a Centralized Hub with Data and Biosamples for Researchers Around the World Newport Beach, CA (June 18, 2021) – CureDuchenne, a leading global nonprofit focused on finding […]
June 1, 2021 VISION-DMD 24-week study readout: Update from Santhera Dear U.S. Duchenne community, We are happy to provide an update of the VISION-DMD Phase 2b study conducted by Santhera […]
Results from the first 11 participants enrolled in Study 9001-103 ENDEAVOR showed robust transduction, delivering mean vector genome copies of 3.87 per nucleus Treated patients achieved mean micro-dystrophin expression levels […]
With recent clinical updates from Pfizer, Sarepta and Audenteson their programs in muscular disorders, the timely Gene Therapy for Muscular Disorders arrives as the only meeting dedicated to overcoming the translational […]
Update on Pfizer’s Duchenne gene therapy Phase 3 clinical program In line with our continued efforts to work with the Duchenne community and share information as it becomes available, we […]
